Cargando…

Role of β3-adrenergic receptors in the action of a tumour lipid mobilizing factor

Induction of lipolysis in murine white adipocytes, and stimulation of adenylate cyclase in adipocyte plasma membranes, by a tumour-produced lipid mobilizing factor, was attenuated by low concentrations (10(−7)–10(−5) M) of the specific β3-adrenoceptor antagonist SR59230A. Lipid mobilizing factor (25...

Descripción completa

Detalles Bibliográficos
Autores principales: Russell, S T, Hirai, K, Tisdale, M J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375201/
https://www.ncbi.nlm.nih.gov/pubmed/11875710
http://dx.doi.org/10.1038/sj.bjc.6600086
_version_ 1782154600803991552
author Russell, S T
Hirai, K
Tisdale, M J
author_facet Russell, S T
Hirai, K
Tisdale, M J
author_sort Russell, S T
collection PubMed
description Induction of lipolysis in murine white adipocytes, and stimulation of adenylate cyclase in adipocyte plasma membranes, by a tumour-produced lipid mobilizing factor, was attenuated by low concentrations (10(−7)–10(−5) M) of the specific β3-adrenoceptor antagonist SR59230A. Lipid mobilizing factor (250 nM) produced comparable increases in intracellular cyclic AMP in CHOK1 cells transfected with the human β3-adrenoceptor to that obtained with isoprenaline (1 nM). In both cases cyclic AMP production was attenuated by SR59230A confirming that the effect is mediated through a β3-adrenoceptor. A non-linear regression analysis of binding of lipid mobilizing factor to the β3-adrenoceptor showed a high affinity binding site with a Kd value 78±45 nM and a B(max) value (282±1 fmole mg protein(−1)) comparable with that of other β3-adrenoceptor agonists. These results suggest that lipid mobilizing factor induces lipolysis through binding to a β3-adrenoceptor. British Journal of Cancer (2002) 86, 424–428. DOI: 10.1038/sj/bjc/6600086 www.bjcancer.com © 2002 The Cancer Research Campaign
format Text
id pubmed-2375201
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23752012009-09-10 Role of β3-adrenergic receptors in the action of a tumour lipid mobilizing factor Russell, S T Hirai, K Tisdale, M J Br J Cancer Experimental Therapeutics Induction of lipolysis in murine white adipocytes, and stimulation of adenylate cyclase in adipocyte plasma membranes, by a tumour-produced lipid mobilizing factor, was attenuated by low concentrations (10(−7)–10(−5) M) of the specific β3-adrenoceptor antagonist SR59230A. Lipid mobilizing factor (250 nM) produced comparable increases in intracellular cyclic AMP in CHOK1 cells transfected with the human β3-adrenoceptor to that obtained with isoprenaline (1 nM). In both cases cyclic AMP production was attenuated by SR59230A confirming that the effect is mediated through a β3-adrenoceptor. A non-linear regression analysis of binding of lipid mobilizing factor to the β3-adrenoceptor showed a high affinity binding site with a Kd value 78±45 nM and a B(max) value (282±1 fmole mg protein(−1)) comparable with that of other β3-adrenoceptor agonists. These results suggest that lipid mobilizing factor induces lipolysis through binding to a β3-adrenoceptor. British Journal of Cancer (2002) 86, 424–428. DOI: 10.1038/sj/bjc/6600086 www.bjcancer.com © 2002 The Cancer Research Campaign Nature Publishing Group 2002-02-01 /pmc/articles/PMC2375201/ /pubmed/11875710 http://dx.doi.org/10.1038/sj.bjc.6600086 Text en Copyright © 2002 The Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Experimental Therapeutics
Russell, S T
Hirai, K
Tisdale, M J
Role of β3-adrenergic receptors in the action of a tumour lipid mobilizing factor
title Role of β3-adrenergic receptors in the action of a tumour lipid mobilizing factor
title_full Role of β3-adrenergic receptors in the action of a tumour lipid mobilizing factor
title_fullStr Role of β3-adrenergic receptors in the action of a tumour lipid mobilizing factor
title_full_unstemmed Role of β3-adrenergic receptors in the action of a tumour lipid mobilizing factor
title_short Role of β3-adrenergic receptors in the action of a tumour lipid mobilizing factor
title_sort role of β3-adrenergic receptors in the action of a tumour lipid mobilizing factor
topic Experimental Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375201/
https://www.ncbi.nlm.nih.gov/pubmed/11875710
http://dx.doi.org/10.1038/sj.bjc.6600086
work_keys_str_mv AT russellst roleofb3adrenergicreceptorsintheactionofatumourlipidmobilizingfactor
AT hiraik roleofb3adrenergicreceptorsintheactionofatumourlipidmobilizingfactor
AT tisdalemj roleofb3adrenergicreceptorsintheactionofatumourlipidmobilizingfactor